nach oben

Wiener klinische Wochenschrift

Erschienen in:

10.05.2019 | Lyme Borreliosis

Evaluation of the clinical relevance of vancomycin for the treatment of Lyme disease

verfasst von: Dr. Gary P. Wormser, M.D., Dr. Alan G. Barbour, M.D.

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 7-8/2023

Einloggen, um Zugang zu erhalten

Summary

Vancomycin is active in vitro and in vivo in mouse systems against Lyme disease borrelia; however, there are no published data on the efficacy of vancomycin in patients with Lyme disease and no convincing theoretical advantages of vancomycin over the currently used and highly effective orally administered antimicrobial agents, including doxycycline, amoxicillin and cefuroxime axetil. In addition, vancomycin may cause a wide variety of potentially serious adverse effects and requires the placement of an intravenous catheter. It is concluded that vancomycin is a much less attractive option for the treatment of patients with early Lyme disease (or any other manifestation of Lyme disease), compared with the antimicrobials currently being used. Based on available evidence, clinical studies to evaluate the safety and efficacy of vancomycin for Lyme disease cannot be recommended.

Vorheriger Artikel Bacteria and protozoa with pathogenic potential in Ixodes ricinus ticks in Viennese recreational areas

Nächster Artikel Borrelial lymphocytoma

Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: Clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43:1089–134.CrossRefPubMed

Ljøstad U, Skogvoll E, Eikeland R, Midgard R, Skarpaas T, Berg A, et al. Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: A multicenter, non-inferiority, double-blind, randomized trial. Lancet Neurol. 2008;7(8):690–5.CrossRefPubMed

Wormser GP, Halperin JJ. Oral doxycycline for neuroborreliosis. Lancet Neurol. 2008;7:665–6.CrossRefPubMed

Kazragis RJ, Dever LL, Jorgensen JH, Barbour AG. In vivo activities of ceftriaxone and vancomycin against Borrelia spp. in the mouse brain and other sites. Antimicrob Agents Chemother. 1996;40:2632–6.CrossRefPubMedPubMedCentral

Wu X, Sharma B, Niles S, O’Connor K, Schilling R, Matluck N, et al. Identifying vancomycin as an effective antibiotic for killing Borrelia burgdorferi. Antimicrob Agents Chemother. 2018;62:e01201-18. https://doi.org/10.1128/AAC.01201-18.CrossRefPubMedPubMedCentral

Harman MW, Hamby AE, Boltyanskiy R, Belperron AA, Bockenstedt LK, Kress H, et al. Vancomycin reduces cell wall stiffness and slows swim speed of the Lyme disease bacterium. Biophys J. 2017;112:746–54.CrossRefPubMedPubMedCentral

Dever LL, Jorgensen JH, Barbour AG. In vitro activity of vancomycin against the spirochete Borrelia burgdorferi. Antimicrob Agents Chemother. 1993;37:1115–21.CrossRefPubMedPubMedCentral

Hunfeld K‑P, Weigand J, Wichelhaus TA, Kekoukh E, Kraiczy P, Brade V. In vitro activity of mezlocillin, meropenem, aztreonam, vancomycin, teicoplanin, ribostamycin, and fusidic acid against Borrelia burgdorferi. Int J Antimicrob Agents. 2001;17:203–8.CrossRefPubMed

Sartakova ML, Dobrikova EY, Terekhova DA, Devis R, Bugrysheva JV, Morozova OV, et al. Novel antibiotic-resistance markers in pGK-12-derived vectors for Borrelia burgdorferi. Gene. 2003;303:131–7.CrossRefPubMed

10.

Sharma B, Brown AV, Matluck NE, Hu LT, Lewis K. Borrelia burgdorferi, the causative agent of Lyme disease, forms drug-tolerant persistor cells. Antimicrob Agents Chemother. 2015;59:4616–24.CrossRefPubMedPubMedCentral

11.

Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 28th ed. Wayne: CLSI; 2018. CLSI Supplement M100.

12.

Bruniera FR, Ferreira FM, Saviolli LR, Bacci MR, Feder D, da Luz Gonçalves Pedreira M, et al. The use of vancomycin with its therapeutic and adverse effects: A review. Eur Rev Med Pharmacol Sci. 2015;19(4):694–700.PubMed

13.

Barbour AG. Borreliaceae. In: Whitman WB, Rainey F, Kämpfer P, Trujillo M, Chun J, DeVos P, Hedlund B, Dedysh S, editors. Bergey’s manual of systematics of archaea and bacteria. 2018. https://doi.org/10.1002/9781118960608.fbm00308.CrossRef

14.

Docobo-Pérez F, López-Rojas R, Domínguez-Herrera J, Jiménez-Mejias ME, Pichardo C, Ibáñez-Martínez J, et al. Efficacy of linezolid versus a pharmacodynamically optimized vancomycin therapy in an experimental pneumonia model caused by methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2012;67:1961–7.CrossRefPubMed

15.

Placencia FX, Kong L, Weisman LE. Treatment of methicillin-resistant Staphylococcus aureus in neonatal mice: Lysostaphin versus vancomycin. Pediatr Res. 2009;65(4):420–4.CrossRefPubMed

16.

Lepak AJ, Zhao M, Andes DR. Comparative pharmacodynamics of telavancin and vancomycin in the neutropenic murine thigh and lung infection models against Staphylococcus aureus. Antimicrob Agents Chemother. 2017; https://doi.org/10.1128/AAC.00281-17.CrossRefPubMedPubMedCentral

17.

Louie A, Boyne MT II, Patel V, Huntley C, Liu W, Fikes S, et al. Pharmacodynamic evaluation of the activities of six parenteral vancomycin products available in the United States. Antimicrob Agents Chemother. 2015;59:622–32.CrossRefPubMed

18.

Dominguez-Herrera J, Lopez-Rojas R, Smani Y, Labrador-Herrera G, Pachon J. Efficacy of ceftaroline versus vancomycin in an experimental foreign-body and systemic infection model caused by bio-film producing methicillin-resistant Staphylococcus epidermidis. Int J Antimicrob Agents. 2016;48:661–5.CrossRefPubMed

19.

Peetermans WE, Hoogeterp JJ, Hazekamp-van Dokkum A‑M, van den Broek P, Mattie H. Anti-staphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection. Antimicrob Agents Chemother. 1990;34:1869–74.CrossRefPubMedPubMedCentral

20.

Moise PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus respiratory tract infections. Clin Pharmacokinet. 2004;43:925–42.CrossRef

21.

Sakoulas G, Geriak M, Nizet V. Is a reported penicillin allergy sufficient grounds to forego the multidimensional antimicrobial benefits of β‑lactam antibiotics? Clin Infect Dis. 2019;68(1):157–64. https://doi.org/10.1093/cid/ciy557.CrossRefPubMed

22.

Forouzesh A, Moise PA, Sakoulas G. Vancomycin ototoxicity: A re-evaluation in an era of increasing doses. Antimicrob Agents Chemother. 2009;53:483–6.CrossRefPubMed

23.

Beach JE, Perrott J, Turgeon RD, Ensom MHH. Penetration of vancomycin into the cerebrospinal fluid: A systematic review. Clin Pharmacokinet. 2017;56(12):1479–90.CrossRefPubMed

24.

Luft BJ, Steinman CR, Neimark HC, Muralidhar B, Rush T, Finkel MF, et al. Invasion of the central nervous system by Borrelia burgdorferi in acute disseminated infection. JAMA. 1992;267:1364–7.CrossRefPubMed

25.

Dattwyler RJ, Luft BJ, Kunkel MJ, Finkel MF, Wormser GP, Rush TJ, et al. Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease. N Engl J Med. 1997;337:289–94.CrossRefPubMed

26.

Wormser GP, Ramanathan R, Nowakowski J, McKenna D, Holmgren D, Visintainer P, et al. Duration of antibiotic therapy for early Lyme disease. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003;138:697–704.CrossRefPubMed

27.

Nowakowski J, Nadelman RB, Sell R, McKenna D, Cavaliere FC, Holmgren D, et al. Long-term follow-up of patients with culture-confirmed Lyme disease. Am J Med. 2003;115:91–6.CrossRefPubMed

28.

Weitzner E, McKenna D, Nowakowski J, Scavarda C, Dornbush R, Bittker S, et al. Long-term assessment of post-treatment symptoms in patients with culture-confirmed early Lyme disease. Clin Infect Dis. 2015;61:1800–6.CrossRefPubMedPubMedCentral

29.

Wormser GP, Schwartz I. Antibiotic treatment of animals infected with Borrelia burgdorferi. Clin Microbiol Rev. 2009;22:387–95.CrossRefPubMedPubMedCentral

30.

Wormser GP, O’Connell S, Pachner AR, Schwartz I, Shapiro ED, Stanek G, et al. Critical analysis of a doxycycline treatment trial of rhesus macaques infected with Borrelia burgdorferi. Diagn Microbiol Infect Dis. 2018;92:183–8.CrossRefPubMedPubMedCentral

31.

Hansen K, Hovmark A, Lebech A‑M, Lebech K, Olsson I, Halkier-Sørensen L, et al. Roxithromycin in Lyme borreliosis: Discrepant results of an in vitro and in vivo animal susceptibility study and a clinical trial in patients with erythema migrans. Acta Derm Venereol. 1992;72(4):297–300.PubMed

32.

Cadavid D, Barbour AG. Neuroborreliosis during relapsing fever: Review of the clinical manifestations, pathology, and treatment of infections in humans and experimental animals. Clin Infect Dis. 1998;26:151–64.CrossRefPubMed

Titel: Evaluation of the clinical relevance of vancomycin for the treatment of Lyme disease
verfasst von: Dr. Gary P. Wormser, M.D.
Dr. Alan G. Barbour, M.D.
Publikationsdatum: 10.05.2019
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift / Ausgabe 7-8/2023
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-019-1505-6

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7-8/2023

PET-CT in the diagnosis of cardiac and pulmonary sarcoidosis

Clinical-Pathological Conference Series from the Medical University of Graz

Correction to: Restoration of antioxidant enzymes in the therapeutic use of selenium in septic patients

MUW researcher of the month

Rückblick: Jahreshauptversammlung 2023 im Billrothhaus

MUW researcher of the month